[Skip to Content]
[Skip to Content Landing]
Article
November 1991

Dosages and Cost-Benefit Comparisons of Drug Therapy

Arch Intern Med. 1991;151(11):2220. doi:10.1001/archinte.1991.00400110078016

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.

Abstract

In the article entitled "Cost-Benefit Issues in the Practice of Internal Medicine" that appeared in the June 1991 issue of the Archives (1991;151:1165-1168), the nadolol dose on page 1166, column 1, lines 32-36, is listed as 40 mg three times daily. The sentence should have read as follows: "Among the most commonly used β-blocking agents, based on most recent wholesale prices, a 1-week course of nadolol (40 mg/d) and atenolol (50 mg/d) are approximately equivalent in cost and remain at least six times as expensive as propanolol hydrochloride (40 mg three times a day)."

First Page Preview View Large
First page PDF preview
First page PDF preview
×